Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas

A-M Hui1, S Kawasaki1, H Imamura1, S Miyagawa1, K Ishii2, T Katsuyama2 and M Makuchii3

1First Department of Surgery, Shinshu University School of Medicine; 2Central Clinical Laboratories, Shinshu University Hospital, Matsumoto, Japan; 3Second Department of Surgery, University of Tokyo, Faculty of Medicine, Tokyo, Japan

Summary Heterogeneity of DNA content in multiple hepatocellular carcinomas (HCCs) was investigated by flow cytometry in 62 tumours from 26 patients who had undergone surgical treatment for multiple synchronous HCCs. Heterogeneity of DNA content was defined (a) when tumours had a different DNA ploidy pattern or (b) when the difference in the DNA index of the aneuploid clone was more than 0.1. A tumour with DNA aneuploidy was observed in 17 (66%) of the 26 patients. Heterogeneity of the DNA content was demonstrated in 12 (46%) out of 26 patients: in ten cases by definition (a) and in two cases by definition (b). Histological examination revealed that, of the 12 patients with a heterogeneous tumour DNA content, seven (58%) had a heterogeneous and the remaining five (42%) had a homogeneous type and grade of differentiation among the tumours, showing the absence of a relationship between histological heterogeneity and DNA content. The present results suggest the clinical relevance of DNA content analysis for identifying the clonal origin of multiple HCCs.

Keywords: hepatocellular carcinoma; DNA content; heterogeneity; flow cytometry

Hepatocellular carcinoma (HCC) is the most common malignancy in Africa and Asia and is associated with a poor prognosis. Surgical resection is the first choice of treatment. However, the frequent development of multiple tumours in patients with chronic viral hepatitis and/or cirrhosis hinders curability. Thus, it is thought important to understand the biological behaviour and clonal origin of different tumours in cases of multiple HCC for evaluation of clinical stage, prediction of post-operative outcome and choice of suitable therapeutic treatments.

Flow cytometric analysis of cellular DNA content has become an increasingly important clinical tool for the evaluation of tumour biological behaviour. Quantitative DNA analysis reflects the total chromosomal content of tumour cells. In terms of the cell nuclear DNA content of HCC, it has been reported (Fujimoto et al, 1991; Chiu et al, 1992) that an aneuploid DNA pattern indicates poor prognosis. With regard to the heterogeneity of the DNA ploidy pattern, HCC has been reported to be mostly homogeneous within the same tumour (Kuo et al, 1987; Nagasue et al, 1993; Ng et al, 1994). However, there have been few studies on the heterogeneity of DNA content among multiple synchronous HCCs. In the present study, we investigated tumour DNA heterogeneity in patients with multiple synchronous HCCs.

MATERIALS AND METHODS

Sixty-two tumours from 26 patients who had undergone surgical treatment for multiple HCCs at the First Department of Surgery, Shinshu University Hospital, between October 1989 and August 1994, were studied. Two patients each had four tumours, six patients had three tumours and the remaining 18 patients had two tumours each. There were 17 men and nine women with a mean age of 64.5 ± 6.3 (s.d.) years (range, 54–82 years). In all patients, histological examination of the non-cancerous tissue demonstrated chronic hepatitis, precirrhosis or cirrhosis. Three patients were positive for hepatitis B virus, 22 patients for hepatitis C virus and one patient for both viruses. The tumour size ranged from 0.6 to 6.0 cm with an average of 2.4 ± 1.1 cm (mean ± s.d.). These 62 tumours in the present study were considered to be of potentially multifocal origin as they did not meet the following criteria of intrahepatic metastasis: multiple HCCs were diagnosed as metastatic in origin from a single tumour (a) when they were components of portal vein tumour thrombi, i.e. tumours apparently growing in contiguity with portal vein tumour thrombi or (b) when they were distributed as multiple small-satellite nodules surrounding a large main tumour (Kanai et al, 1987; Oda et al, 1992; Tsuda et al, 1992).

A cell nucleus suspension was obtained from a paraffin-embedded block of a surgically resected specimen, following the methods of Hedley with some modifications (Hedley et al, 1983; Hui et al, 1994). Briefly, the tumour and non-tumour parts were obtained from resected specimens. Three 50-μm-thick sections were cut, in addition to a 5-μm-thick section before and after each series of 50-μm-thick sections. The 5-μm-thick section was stained with haematoxylin and eosin in order to evaluate the pathological features and to assess the tumour area in the section, then accordingly, the tumour was trimmed from the 50-μm-thick section. The tissue was dewaxed, rehydrated and then digested with pepsin. The isolated nuclei were stained according to the method described previously (Vinelev et al, 1983). Cell nuclear DNA content was analysed using a FACScan (Becton Dickinson, Mountain View, CA, USA) with Cellfit doublet discriminator software. The histogram was derived from up to 15 000 cells. The instrument was calibrated with chicken erythrocyte nuclei. As external controls, sections from non-tumour liver within the same surgical specimen were processed.
RESULTS

The results of histological and flow cytometric studies of the 62 tumours from 26 patients with multiple synchronous HCCs are summarized in Table 1. The tumours had a trabecular pattern in 53 cases (85.5%), a compact pattern in six (9.7%), a pseudoglandular pattern in two (3.2%) and a solid pattern in one (1.6%). Among the 26 patients, six (23.1%) had heterogeneous and 20 (76.9%) had homogeneous histological type among the multiple tumours. Regarding the grade of tumour differentiation, 20 tumours (32.3%) were well differentiated, 33 (53.2%) were moderately differentiated and nine (14.5%) were poorly differentiated. The histological type and the grades of differentiation among the multiple tumours were identical in 9 of the 26 cases and different in the remaining 17. A tumour with aneuploid DNA was observed in 17 (65.4%) of the 26 patients. Among the 62 tumours, 35 (56.4%) were diploid (pattern I) and 27 (43.5%) were aneuploid, of which 14 tumours belonged to pattern II and the remaining 13 to pattern III. DNA heterogeneity among multiple tumours was observed in 12 out of 26 patients (46.2%, cases 15–26), among which the DNA content difference represented the diploid–aneuploid type in ten (cases 17–26). In cases 15 and 16, the difference in DI of the aneuploid clone was more than 0.1, although both of the tumours were aneuploid (pattern III). Of the 12 patients with tumours showing DNA heterogeneity, seven (58.3%) had the heterogeneous (cases 15, 18, 19, 20, 23, 24 and 26) and the remaining five (41.7%) had the homogeneous histological type and grade of tumour differentiation.

DISCUSSION

Quantitative DNA analysis reflects the total chromosomal content of tumour cells and it can now be conducted rapidly and reliably using flow cytometry. Flow cytometric DNA analysis has become a valuable adjunct to the clinical and histopathological assessment of cancers.
### Table 1: Histopathological features and DNA content in multiple hepatocellular carcinoma

| Case | Tumour | Histological type | Differentiation | DNA analysis | Histological type heterogeneity | Differentiation heterogeneity | DNA content heterogeneity |
|------|--------|-------------------|-----------------|--------------|-------------------------------|-------------------------------|----------------------------|
|      |        |                   | Pattern        | CV (%)       | DI                            |                               |                            |
| 1    | T1     | Trabecular        | Well           | I            | 6.8                           | 1.00                          | No                         | No                         |
|      | T2     | Trabecular        | Well           | I            | 3.6                           | 1.00                          | No                         | No                         |
| 2    | T1     | Trabecular        | Well           | I            | 6.1                           | 1.02                          | No                         | No                         |
|      | T2     | Trabecular        | Well           | I            | 5.4                           | 1.02                          | No                         | No                         |
| 3    | T1     | Trabecular        | Well           | I            | 4.2                           | 1.05                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | I            | 4.6                           | 1.02                          | No                         | Yes                        |
|      | T3     | Trabecular        | Well           | I            | 3.5                           | 1.02                          | Yes                        | No                         |
| 4    | T1     | Trabecular        | Well           | I            | 5.8                           | 1.08                          | No                         | Yes                        |
|      | T2     | Trabecular        | Moderate       | I            | 7.3                           | 1.03                          | No                         | Yes                        |
| 5    | T1     | Trabecular        | Moderate       | I            | 7.6                           | 1.06                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | I            | 6.1                           | 1.03                          | No                         | No                         |
|      | T3     | Trabecular        | Poor           | I            | 5.4                           | 1.03                          | Yes                        | No                         |
| 6    | T1     | Trabecular        | Moderate       | I            | 4.0                           | 0.98                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | I            | 4.5                           | 0.95                          | No                         | No                         |
| 7    | T1     | Trabecular        | Moderate       | I            | 6.7                           | 1.01                          | No                         | No                         |
|      | T2     | Solid             | Poor           | I            | 5.4                           | 1.01                          | No                         | No                         |
|      | T3     | Trabecular        | Well           | I            | 7.5                           | 1.02                          | No                         | No                         |
|      | T4     | Trabecular        | Well           | I            | 7.5                           | 0.96                          | No                         | No                         |
| 8    | T1     | Trabecular        | Moderate       | I            | 6.4                           | 1.06                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | I            | 4.2                           | 1.10                          | No                         | No                         |
|      | T3     | Trabecular        | Moderate       | I            | 5.8                           | 1.04                          | No                         | No                         |
| 9    | T1     | Trabecular        | Moderate       | I            | 4.2                           | 1.08                          | No                         | No                         |
|      | T2     | Trabecular        | Well           | I            | 4.8                           | 0.94                          | No                         | No                         |
| 10   | T1     | Trabecular        | Well           | II           | 3.9                           | 1.22                          | No                         | No                         |
|      | T2     | Pseudoglandular   | Moderate       | II           | 5.9                           | 1.31                          | No                         | No                         |
| 11   | T1     | Compact           | Poor           | II           | 6.5                           | 1.14                          | Yes                        | No                         |
|      | T2     | Trabecular        | Poor           | II           | 4.5                           | 1.16                          | Yes                        | No                         |
| 12   | T1     | Trabecular        | Well           | II           | 4.7                           | 1.19                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | II           | 4.3                           | 1.15                          | No                         | No                         |
| 13   | T1     | Compact           | Moderate       | II           | 4.6                           | 1.18                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | II           | 4.7                           | 1.18                          | No                         | No                         |
| 14   | T1     | Trabecular        | Moderate       | III           | 5.3                           | 1.29                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | III           | 4.6                           | 1.19                          | No                         | No                         |
| 15   | T1     | Trabecular        | Moderate       | III           | 5.2                           | 1.22                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | III           | 6.4                           | 1.35                          | No                         | No                         |
| 16   | T1     | Trabecular        | Moderate       | III           | 8.7                           | 1.24                          | No                         | Yes                        |
|      | T2     | Trabecular        | Moderate       | III           | 4.2                           | 1.43                          | No                         | Yes                        |
| 17   | T1     | Compact           | Poor           | I             | 3.5                           | 0.97                          | No                         | No                         |
|      | T2     | Compact           | Poor           | II             | 8.4                           | 1.11                          | Yes                        | No                         |
| 18   | T1     | Trabecular        | Moderate       | I             | 5.8                           | 0.95                          | No                         | Yes                        |
|      | T2     | Trabecular        | Well           | II             | 7.3                           | 0.82                          | No                         | Yes                        |
| 19   | T1     | Trabecular        | Well           | I             | 4.9                           | 0.96                          | No                         | Yes                        |
|      | T2     | Trabecular        | Poor           | I             | 4.7                           | 0.93                          | No                         | Yes                        |
|      | T3     | Trabecular        | Well           | II             | 7.0                           | 0.90                          | No                         | Yes                        |
| 20   | T1     | Trabecular        | Well           | I             | 4.6                           | 1.06                          | No                         | Yes                        |
|      | T2     | Trabecular        | Well           | II             | 4.9                           | 1.13                          | No                         | Yes                        |
|      | T3     | Trabecular        | Well           | II             | 4.3                           | 1.22                          | No                         | Yes                        |
| 21   | T1     | Trabecular        | Moderate       | I             | 6.1                           | 0.94                          | No                         | No                         |
|      | T2     | Trabecular        | Moderate       | III           | 7.3                           | 0.79                          | No                         | Yes                        |
| 22   | T1     | Trabecular        | Moderate       | I             | 8.1                           | 0.94                          | No                         | Yes                        |
|      | T2     | Trabecular        | Moderate       | III           | 5.9                           | 2.16                          | No                         | Yes                        |
| 23   | T1     | Trabecular        | Moderate       | I             | 5.6                           | 0.91                          | No                         | No                         |
|      | T2     | Pseudoglandular   | Moderate       | III           | 6.9                           | 1.36                          | Yes                        | Yes                        |
| 24   | T1     | Trabecular        | Moderate       | I             | 7.5                           | 0.99                          | No                         | Yes                        |
|      | T2     | Trabecular        | Well           | III           | 6.0                           | 1.46                          | No                         | Yes                        |
| 25   | T1     | Trabecular        | Moderate       | I             | 5.0                           | 1.01                          | No                         | Yes                        |
|      | T2     | Trabecular        | Moderate       | I             | 7.0                           | 1.05                          | No                         | Yes                        |
|      | T3     | Trabecular        | Moderate       | III           | 4.6                           | 1.25                          | No                         | Yes                        |
| 26   | T1     | Trabecular        | Moderate       | I             | 6.5                           | 0.93                          | Yes                        | Yes                        |
|      | T2     | Trabecular        | Moderate       | II             | 8.1                           | 0.82                          | Yes                        | Yes                        |
|      | T3     | Compact           | Poor           | III             | 4.8                           | 1.77                          | Yes                        | Yes                        |
|      | T4     | Compact           | Poor           | III             | 6.3                           | 1.93                          | Yes                        | Yes                        |

1DNA ploidy pattern; CV, coefficient of variation; DI, DNA index; T, tumour.
Although intratumoral heterogeneity of DNA content has been observed in carcinomas of various organs (Vindelov et al, 1980; Quirk et al, 1983; Ljungberg et al, 1985; Sasaki et al, 1988; Sasaki et al, 1991), HCC is generally thought to be homogeneous within the tumour in terms of DNA content (Kuo et al, 1987; Nagase et al, 1993; Ng et al, 1994), indicating that single sampling is sufficient for deciding the DNA ploidy pattern in patients with solitary HCC. In the present study, three 50-µm sections were prepared for flow cytometry procedures. Considering that materials are usually taken by one-site sampling in studies using fresh tissue, the results obtained from paraffin-embedded blocks, as in the present study, are considered more representative of the whole tumour than those from fresh materials, at least in terms of DNA content.

It has been shown that DNA content analysis is an important predictor of prognosis, which is better in diploid than in aneuploid tumours (Fujimoto et al, 1991; Chiu et al, 1992), although some authors have suggested that the advanced tumour stage of large lesions may negate the influence of DNA ploidy status on patient outcome (McEntee et al, 1992). These studies were limited to analysis of a single tumour nodule in patients with HCC. However, multiple HCCs occur in some cases. Heterogeneity of DNA content between different nodules, if present, may influence the DNA content status for predicting prognosis. In the present investigation, it was demonstrated that heterogeneity of DNA content among different tumour nodules occurred in 46% of synchronous multiple HCCs, indicating that analysis of the DNA content of every tumour is necessary for determining the prognosis in this disease.

Heterogeneity of DNA content in synchronous multiple HCCs has been demonstrated previously by Feulgen DNA analysis (Kuo et al, 1987) and flow cytometric DNA analysis (Nagase et al, 1992). Unfortunately, however, the number of cases investigated was limited (14 cases in each study). The incidence of heterogeneity was 29% in the former study and 36% in the latter, which was lower than in our study (46%). There are two possible reasons for the discrepancy between the previous studies and ours. First, the previous studies included only patients with two tumour nodules, whereas in our study eight patients had more than two nodules. Second, the previous studies investigated heterogeneity simply by classifying tumours as either diploid or aneuploid (Nagase et al, 1992), or by roughly comparing their DNA ploidy profiles (Kuo et al, 1987). By contrast, in the present study, heterogeneity of DNA content was considered not only when a different DNA ploidy pattern was observed, but also when a different DI (difference > 0.1) was demonstrated among the tumours with an aneuploid pattern.

Heterogeneity by histological criteria (histological type and grade of tumour differentiation) was observed in 16 (62%) of the 26 patients with synchronous multiple HCCs, and there seemed to be no relationship between heterogeneity of histological appearance and DNA content (Table 1).

Genetic and/or chromosomal analyses have demonstrated that solitary HCCs are of monoclonal origin (Esumi et al, 1986; Aihara et al, 1996). On the other hand, the clonal origin of multiple HCCs has been classified conventionally as multifocal or metastatic, i.e. polyclonal or monoclonal, based mainly on macro- and microscopic features. However, it has usually been difficult to determine clonal origin in clinical practice. Integrated HBV DNA has been used as a marker of HCC clonality, but this is applicable only to a portion of patients who have hepatitis B virus infection (Esumi et al, 1986; Tsuda et al, 1988; Sakamoto et al, 1989; Hsu et al, 1991). In our present series, only four patients harboured hepatitis B virus. Recently, examinations of chromosomal allele loss patterns (Tsuda et al, 1992) and patterns of p53 gene mutation (Oda et al, 1992) have been reported to be useful for diagnosis of multifocal HCC. However, these methods are not totally ideal because p53 gene mutation and chromosomal allele loss were detected in only 60–70% of multiple HCCs. These findings showed that judgement of the origin of multiple HCCs should be made on a comprehensive basis, taking into account both morphology and other criteria such as DNA content.

Assuming that single HCCs are monoclonal and that their DNA content remains homogeneous during tumour growth, the difference in DNA content among multiple tumours strongly indicates their different clonal origin. However, analysis of DNA content must be considered limited, as it only reflects the chromosomal content of tumour cells, and a cell with a balanced gain or loss of chromosomes, or with structural rearrangements, will not be detected. Also, it can not give conclusive information on the clonal origin in cases showing a homogeneous DNA pattern, as tumours of different clonal origin may well present the same DNA ploidy pattern. In our series of multiple HCCs, multifocal origin was identified in 12 (46%) of the 26 patients by quantitative analysis of DNA content. In the remaining 14 (56%) cases in which the DNA content was homogeneous among the tumours, their clonal origin still remained undetermined. Comparing the various genetic methods for analysis of multifocal HCC, quantitative analysis of DNA content seems less specific, but it is simple and technically convenient. In order to estimate the value of quantitative DNA content analysis for deciding the clonal origin of multiple HCCs, further investigations such as comparative studies of genetic methods in a single series of patients with synchronous multiple HCCs will be necessary.

REFERENCES

Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M and Imaoka S (1996) Clonal analysis of preneoplastic lesion of hepatocellular carcinoma. Gastroenterology 111: 455-461.

Chiu JH, Kao HL, Wu LH, Chang HM and Lui WY (1992) Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J Clin Invest 89: 539-545.

Esumi M, Aritaka T, Arii M, Suzuki K, Tanikawa K, Mizuo H, Mima T and Shikata T (1986) Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res 46: 5767-5771.

Fujimoto J, Okamoto E, Yamakana N, Toyosaka A and Mitsusho M (1991) Flow cytometric DNA analysis of hepatocellular carcinoma. Cancer 67: 939-944.

Hedley DW, Friedlander ML, Taylor IW, Rugg CA and Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335.

Hiddemann W, Schumann J, Andreeff M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF and Sandberg AA (1984) Convention on nomenclature for DNA flow cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytofugent 13: 181-183.

Hsu HC, Chioo TJ, Chen JY, Lee CS, Lee PH and Peng SY (1991) Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 13: 923-928.

Hui AM, Iabosho M, Kato H, Tachimori Y, Watanabe H and Hirota T (1994) Flow cytometric DNA analysis of submucosal carcinoma of the esophagus. Jpn J Clin Oncol 24: 26-31.

Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makukuchi M, Yamasaki S, Hasegawa H, Takayasu K, Moriyama N and Shimosato Y (1987) Pathology of small hepatocellular carcinoma: a proposal for a new gross classification. Cancer 60: 810-819.

Kuo SH, Shen JC, Chen DS, Sung JL, Lin CC and Hsu HC (1987) DNA clonal heterogeneity of hepatocellular carcinoma demonstrated by Feulgen-DNA analysis. Liver 7: 350-363.

British Journal of Cancer (1997) 76(3), 335–339 © Cancer Research Campaign 1997
Heterogeneity of DNA content

Ljungberg B, Stenling R and Roos G (1985) DNA content in renal cell carcinoma with reference to tumour heterogeneity. Cancer 56: 503–508

McEntee GP, Batts KA, Katzmann JA, Ilstrup DM and Nagorney DM (1992) Relationship of nuclear DNA content to clinical and pathologic findings in patients with primary hepatic malignancy. Surgery 111: 376–379

Nagase N, Kohno H, Chang YC, Yamanoi A, Kimoto T, Takemoto Y and Nakamura T (1992) DNA ploidy pattern in synchronous hepatocellular carcinomas. J Hepatol 16: 208–214

Nagase N, Kohno H, Hayashi T, Yamanoi A, Uchida M, Takemoto Y, Makino Y, Ono T, Hayashi J and Nakamura T (1993) Lack of intratumoral heterogeneity in DNA ploidy pattern of hepatocellular carcinoma. Gastroenterology 105: 1449–1454

Ng IOL, Lai ECS, Ho JCW, Cheung LKN, Ng MMT and So MKP (1994) Flow cytometric analysis of DNA ploidy in hepatocellular carcinoma. Am J Clin Pathol 102: 80–86

Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirohashi S (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinomas. Cancer Res 52: 3674–3678

Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M and Hosoda Y (1989) Multicentric development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 13: 1064–1066

Sasaki K, Hashimoto T, Kawachino K and Takahashi M (1988) Intratumoural origional differences in DNA ploidy of gastrointestinal carcinomas. Cancer 62: 2569–2575

Sasaki K, Murakami T, Murakami T and Nakamura M (1991) Intratumoural heterogeneity in DNA ploidy of esophageal cell carcinomas. Cancer 68: 2403–2406

Tsuda H, Hirohashi S, Shimosato Y, Terata M and Hasegawa H (1988) Clonal origin of atypical adenomatous hyperplasia of liver and clonal identity with hepatocellular carcinoma. Gastroenterology 95: 1664–1666

Tsuda H, Oda T, Sakamoto M and Hirohashi S (1992) Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin. Cancer Res 52: 1504–1509

Quirke P, Dyson JED, Dixon MF, Bird CC and Joslin CA (1985) Heterogeneity of colorectal adenocarcinomas evaluated by flow cytometry and histopathology. Br J Cancer 51: 99–106

Vindelov LL, Hansen HH, Christensen IJ, Spang-Thomsen M, Hirsch FR, Hansen M and Nissen NI (1980) Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res 40: 4295–4300

Vindelov LL, Christensen IJ and Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323–327